Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 5,411 |
|
|||||
| News | - | ||||||
| Day High | 1.3418 | Low High |
|||||
| Day Low | 1.28 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Artelo Biosciences Inc | ARTL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.0318 | 2.43% | 1.3418 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.31 | 1.28 | 1.3418 | 1.3418 | 1.31 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 53 | 5,411 | $ 1.32 | $ 7,160 | - | 1.15 - 2.98 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 14 | $ 1.32 | USD |
Artelo Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 4.27M | 3.19M | - | 0 | -9.29M | -2.91 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Artelo Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARTL Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.46 | 1.46 | 1.25 | 1.31 | 16,881 | -0.1182 | -8.10% |
| 1 Month | 1.45 | 1.5999 | 1.25 | 1.42 | 9,356 | -0.1082 | -7.46% |
| 3 Months | 1.37 | 1.75 | 1.25 | 1.50 | 15,650 | -0.0282 | -2.06% |
| 6 Months | 1.44 | 1.75 | 1.15 | 1.42 | 17,088 | -0.0982 | -6.82% |
| 1 Year | 2.76 | 2.98 | 1.15 | 1.83 | 80,239 | -1.42 | -51.38% |
| 3 Years | 1.27 | 7.20 | 0.2599 | 1.04 | 965,975 | 0.0718 | 5.65% |
| 5 Years | 4.95 | 7.20 | 0.2599 | 1.42 | 1,262,550 | -3.61 | -72.89% |
Artelo Biosciences Description
| Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approaches to cannabinoid-based therapies, including those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds that promote the effectiveness of the endocannabinoid system. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease. |
